SCHEDULE 13D/A: Cevian Capital Boosts Stake in Smith & Nephew to 8.50%, Valued Over $1 Billion

Cevian Capital II GP Limited has significantly increased its beneficial ownership in medical technology firm Smith & Nephew PLC, now holding 8.50% of outstanding shares with an aggregate investment exceeding $1 billion.

Summary

• Cevian Capital II GP Limited, the reporting person, has acquired an aggregate of 74,469,925 Ordinary Shares of Smith & Nephew PLC.
• This stake represents 8.50% of the Issuer's Ordinary Shares, calculated based on 875,945,333 shares reported outstanding as of May 31, 2025.
• The total consideration for these shares, including brokerage commission, is approximately USD $1,008,911,855.
• The purchases were funded out of the Cevian Funds' general working capital and were made using British Pounds, with a conversion rate of USD $1.35945 for each GBP 1.00.
• Recent transactions within the past sixty days, from May 14, 2025, to June 12, 2025, show continuous purchases of Ordinary Shares at prices ranging from $14.38 to $15.23 per share.

Sentiment

Score: 7

Explanation: The filing reports a significant increase in beneficial ownership by Cevian Capital, a known activist investor. While purely factual, such a substantial investment by a major fund is generally perceived as a positive signal of confidence or potential for future strategic initiatives, which could be beneficial for the company.

Positives

• Cevian Capital, a prominent activist investor, has significantly increased its stake, potentially signaling confidence in Smith & Nephew's future prospects or an intent to drive value creation.
• The substantial investment of over $1 billion by Cevian Capital demonstrates a strong commitment to the company.

Future Outlook

This filing does not contain explicit forward-looking statements or guidance from the Issuer or the Reporting Person regarding future performance or strategic direction beyond the reported ownership.

Industry Context

Smith & Nephew PLC operates in the global medical technology industry, specializing in orthopaedics, advanced wound management, and sports medicine. Cevian Capital's increased stake in the company suggests a strategic interest in the sector or the company's specific position within it, potentially aiming to influence corporate strategy or governance.

Stakeholder Impact

• Shareholders: The increased stake by Cevian Capital could lead to increased scrutiny on management performance, potential strategic changes, or a push for enhanced shareholder value.
• Company Management: May face increased engagement or pressure from Cevian Capital regarding operational efficiency, capital allocation, or strategic direction.

Next Steps

• Cevian Capital II GP Limited will continue to hold and potentially adjust its stake in Smith & Nephew PLC.
• Further Schedule 13D amendments will be filed if there are material changes to their beneficial ownership or investment intent.

Key Dates

Keywords

Smith & Nephew PLC, Cevian Capital, Schedule 13D, beneficial ownership, equity stake, medical technology, investment, ordinary shares